Evaluation of Heparin Bonded Vascular Graft Versus Standard Graft in Prosthetic Arteriovenous Access for Hemodialysis
- Conditions
- Hemodialysis Fistula Thrombosis
- Interventions
- Procedure: Prosthetic AV graft implantation
- Registration Number
- NCT00737620
- Lead Sponsor
- Shaare Zedek Medical Center
- Brief Summary
The majority of bridge graft fistula with polytetrafluoroethylene (PTFE) for hemodialysis access will develop stenosis at the venous anastomosis and eventually will fail. Aspirin have been used for many years as a prophylactic drug therapy to prevent thrombosis but good clinical evidence for its benefit is lacking. Many drugs have been used to reduce intimal hyperplasia in animal models. Until recently there has been little success in clinical trials of anti-inflammatory, antiproliferative, antiplatelet, antithrombotic or calcium channel blocking drugs. Recently a major breakthrough was done by GORE when introducing the new heparin bonded PTFE graft by covalent attachment. This trial is planed to assess and compare between the GORE-TEX® PROPATEN vascular graft versus unmodified ePTFE grafts the patency and complication.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 160
- All the patients who are scheduled for the creation of a new prosthetic access with informed consent will be enrolled in the trial
- Investigators will attempt to enroll a male:female ratio of patients representative of their current patient population
- Anticoagulation therapy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description propaten graft Prosthetic AV graft implantation - Standard graft Prosthetic AV graft implantation -
- Primary Outcome Measures
Name Time Method Patency of AV fistula Study period
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Shaare Zedek Medical Center, Jerusalem
🇮🇱Jerusalem, Israel